<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01969955</url>
  </required_header>
  <id_info>
    <org_study_id>CH-L-031</org_study_id>
    <nct_id>NCT01969955</nct_id>
  </id_info>
  <brief_title>Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer</brief_title>
  <official_title>A Phase II Trial of Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer After Failure of Platinum Doublet (Except Pemetrexed) Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of nab-paclitaxel monotherapy in&#xD;
      previously treated advanced or metastatic squamous lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a novel, solvent-free,&#xD;
      albumin-bound nanoparticle form of paclitaxel designed to avoid problems associated with&#xD;
      solvents used in Taxol. And albumin-bound paclitaxel was characterized with high tolerated&#xD;
      doses with greater efficacy, and with greater concentration in tumor tissue compared with&#xD;
      normal tissues. A multicenter randomized controled trial (coded as CA031) showed that&#xD;
      nab-paclitaxel in combination with carboplatin had higher response rate than traditional&#xD;
      paclitaxel plus carboplatin, especially in squamous lung cancer. This is a single center,&#xD;
      non-randomized, open-label Phase II clinical study to investigate the efficacy and&#xD;
      tolerability of nab-paclitaxel monotherapy in previously treated advanced or metastatic&#xD;
      squamous lung cancer after failure of platinum-based doublet therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>up to one year</time_frame>
    <description>Percentage of patients who achieve partial response (PR) or complete response (CR) based on Response Evaluation Criteria In Solid Tumors (RECIST).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>up to 15 months</time_frame>
    <description>Measure of time from study treatment to disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Measure of time from study treatment to patient's death or lost to follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>up to 15 months</time_frame>
    <description>Determine the score change of quality of life between pre- and post-treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>up to 18 months</time_frame>
    <description>Percentage of patients who experience an adverse event during this study.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>secreted protein acidic and rich in cysteine (SPARC) expression level in tumor issues</measure>
    <time_frame>up to 15 months</time_frame>
    <description>Correlationship between secreted protein acidic and rich in cysteine (SPARC) expression in tumor issue and the efficacy of nab-paclitaxel or prognosis of patients</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Squamous Cell Carcinoma of Lung</condition>
  <arm_group>
    <arm_group_label>nanoparticle albumin-bound paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nanoparticle albumin-bound paclitaxel is given at 130 mg/m2 intravenously on day 1 and 8, every 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nanoparticle albumin-bound paclitaxel</intervention_name>
    <description>Nanoparticle albumin-bound paclitaxel is given at 130 mg/m2 intravenously on day 1 and 8, every 21 days.</description>
    <arm_group_label>nanoparticle albumin-bound paclitaxel</arm_group_label>
    <other_name>Abraxane, nab-paclitaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed-consent form;&#xD;
&#xD;
          2. Age no less than 18 years;&#xD;
&#xD;
          3. Histologically confirmed locally advanced or metastatic squamous lung cancer;&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) 0-2 with life expectation of no less than 12&#xD;
             weeks;&#xD;
&#xD;
          5. RECIST measurable lesions;&#xD;
&#xD;
          6. Disease progression after failure of platinum-based doublet therapy;&#xD;
&#xD;
          7. Adequate liver/renal/bone marrow function;&#xD;
&#xD;
          8. Human Chorionic Gonadotropin (HCG) test negative for female with contraception&#xD;
             measures until 3 months after study end;&#xD;
&#xD;
          9. Compliance, and can be followed up regularly.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breast-feeding female, or not willing to take contraception measures&#xD;
             during study;&#xD;
&#xD;
          2. Radiotherapy within 30 days, systematic therapy within 21 days;&#xD;
&#xD;
          3. Serious infection requiring antibiotics intervention during recruitment;&#xD;
&#xD;
          4. Allergic to study drug;&#xD;
&#xD;
          5. Require concurrent biological target therapy;&#xD;
&#xD;
          6. More than grade 1 neuropathy;&#xD;
&#xD;
          7. Uncontrolled brain metastasis or mental illness;&#xD;
&#xD;
          8. Congestive heart failure, uncontrolled cardiac arrhythmia, etc;&#xD;
&#xD;
          9. Other malignancy within 5 years;&#xD;
&#xD;
         10. Can't be followed up or obey protocol;&#xD;
&#xD;
         11. Ineligible by the judge of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junling Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junling Li</last_name>
    <phone>86-13801178891</phone>
    <email>drlijunling@vip.163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer institute and hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junling Li</last_name>
      <email>drlijunling@vip.163.com</email>
    </contact>
    <investigator>
      <last_name>Junling Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>October 22, 2013</study_first_submitted>
  <study_first_submitted_qc>October 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2013</study_first_posted>
  <last_update_submitted>April 24, 2014</last_update_submitted>
  <last_update_submitted_qc>April 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>LI Junling</investigator_full_name>
    <investigator_title>Professor and chief physician</investigator_title>
  </responsible_party>
  <keyword>nanoparticle albumin-bound paclitaxel</keyword>
  <keyword>Squamous Cell Carcinoma of Lung</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

